Kamada (NASDAQ:KMDA) Shares Break Below 200 Day Moving Average – Here’s What Happened

Kamada Ltd. (NASDAQ:KMDA) crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $7.85 and traded as low as $7.59. Kamada shares last traded at $7.69, with a volume of 87,325 shares traded.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on KMDA. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research note on Tuesday, July 21st. UBS Group reissued a “buy” rating and issued a $15.00 price target on shares of Kamada in a research note on Friday, September 18th. Weiss Ratings upgraded shares of Kamada from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, October 9th. William Blair set a $15.00 price objective on Kamada in a research report on Tuesday, July 21st. Finally, Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 15th. Four research analysts have rated the stock with a Buy rating. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $13.50.

Kamada Trading Up 3.0%

The stock has a market cap of $450.30 million, a P/E ratio of 20.61, a PEG ratio of 0.64 and a beta of 0.89. The stock’s fifty day moving average price is $8.14 and its 200 day moving average price is $7.85.

Kamada (NASDAQ:KMDA) last announced its earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. Kamada had a net margin of 11.60% and a return on equity of 8.37%. The business had revenue of $54.92 million during the quarter, compared to the consensus estimate of $50.84 million. As a group, sell-side analysts forecast that Kamada Ltd. will post 0.48 earnings per share for the current year.

Kamada Cuts Dividend

The company also recently declared an annual dividend, which was paid on Thursday, September 17th. Investors of record on Thursday, August 27th were given a dividend of $0.17 per share. This represents a dividend yield of 206.0%. This is a decrease from Kamada’s previous annual dividend of $0.25. The ex-dividend date of this dividend was Thursday, August 27th. Kamada’s payout ratio is 34.21%.

Hedge Funds Weigh In On Kamada

An institutional investor recently raised its stake in Kamada stock. Aristides Capital LLC lifted its holdings in shares of Kamada Ltd. (NASDAQ:KMDA) by 4.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,015 shares of the biotechnology company’s stock after buying an additional 1,430 shares during the period. Aristides Capital LLC owned approximately 0.06% of Kamada worth $233,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is an Israeli biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapies. The company’s products are designed to treat rare diseases, immune deficiencies and other serious medical conditions, with an emphasis on specialty biologic medicines and immunoglobulin-based treatments.

Kamada’s portfolio includes Glassia, an alpha-1 antitrypsin augmentation therapy for patients with alpha-1 antitrypsin deficiency; KEDRAB, a human rabies immune globulin used for post-exposure prophylaxis; WINRHO SDF, an immune globulin product; and CYTOGAM, a cytomegalovirus immune globulin.